MX337433B - Apoptosis de celulas cancerosas. - Google Patents
Apoptosis de celulas cancerosas.Info
- Publication number
- MX337433B MX337433B MX2012002992A MX2012002992A MX337433B MX 337433 B MX337433 B MX 337433B MX 2012002992 A MX2012002992 A MX 2012002992A MX 2012002992 A MX2012002992 A MX 2012002992A MX 337433 B MX337433 B MX 337433B
- Authority
- MX
- Mexico
- Prior art keywords
- cancer cell
- cell apoptosis
- therapeutic agent
- dexanabinol
- farnesyltransferase
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 2
- 102000003893 Histone acetyltransferases Human genes 0.000 abstract 2
- 108090000246 Histone acetyltransferases Proteins 0.000 abstract 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 102000003945 NF-kappa B Human genes 0.000 abstract 2
- 108010057466 NF-kappa B Proteins 0.000 abstract 2
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 abstract 2
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 108091007914 CDKs Proteins 0.000 abstract 1
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 abstract 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 abstract 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 abstract 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 1
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 abstract 1
- 102000007317 Farnesyltranstransferase Human genes 0.000 abstract 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 abstract 1
- SSQJFGMEZBFMNV-PMACEKPBSA-N dexanabinol Chemical compound C1C(CO)=CC[C@@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@H]21 SSQJFGMEZBFMNV-PMACEKPBSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a un agente terapéutico capaz de producir un efecto directo o indirecto sobre las proteínas N-metil-D-aspartato (NMDA), Ciclooxigenasa-2 (COX-2), Factor de necrosis tumoral alfa (TNF-a), Factor nuclear kappa B (NFKB), Quinasas dependientes de la ciclina, por ejemplo la CDK2/A y la CDK5/p25, Histona acetil transferasa (HAT) y Farnesiltransferasa, de forma simultánea, secuencial o separada. Se describe el dexanabinol, o sus derivados, como el agente terapéutico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0915877.5A GB0915877D0 (en) | 2009-09-10 | 2009-09-10 | Cancer cell apoptosis |
| PCT/GB2010/001710 WO2011030106A1 (en) | 2009-09-10 | 2010-09-10 | Cancer cell apoptosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012002992A MX2012002992A (es) | 2012-07-17 |
| MX337433B true MX337433B (es) | 2016-03-04 |
Family
ID=41228122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002992A MX337433B (es) | 2009-09-10 | 2010-09-10 | Apoptosis de celulas cancerosas. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20120190735A1 (es) |
| EP (1) | EP2475364A1 (es) |
| JP (2) | JP5930204B2 (es) |
| KR (1) | KR20120090060A (es) |
| CN (2) | CN102573833A (es) |
| AU (1) | AU2010294055B2 (es) |
| BR (1) | BR112012005262A2 (es) |
| CA (1) | CA2771099A1 (es) |
| GB (1) | GB0915877D0 (es) |
| IL (1) | IL218008A (es) |
| IN (1) | IN2012DN02412A (es) |
| MX (1) | MX337433B (es) |
| MY (1) | MY161186A (es) |
| NZ (1) | NZ598652A (es) |
| RU (1) | RU2592230C2 (es) |
| SG (1) | SG178604A1 (es) |
| WO (1) | WO2011030106A1 (es) |
| ZA (1) | ZA201201981B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0713116D0 (en) * | 2007-07-06 | 2007-08-15 | Therapeutics Ltd E | Treatment of melanoma |
| GB0719771D0 (en) * | 2007-10-10 | 2007-11-21 | Therapeutics Ltd E | Dexanabinol in combination with inhibitors of BRAF or MEK for the treatment of melanoma |
| GB0915877D0 (en) * | 2009-09-10 | 2009-10-14 | E Therapeutics Plc | Cancer cell apoptosis |
| GB201207305D0 (en) * | 2012-04-26 | 2012-06-13 | E Therapeutics Plc | Therapy |
| WO2017068349A1 (en) * | 2015-10-23 | 2017-04-27 | E-Therapeutics Plc | Cannabinoid for use in immunotherapy |
| CN116726181B (zh) * | 2023-08-09 | 2023-10-20 | 四川省医学科学院·四川省人民医院 | 抑制nat9基因表达的试剂的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3249109A (en) | 1963-11-01 | 1966-05-03 | Maeth Harry | Topical dressing |
| US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US4144317A (en) | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
| US4262003A (en) | 1975-12-08 | 1981-04-14 | Alza Corporation | Method and therapeutic system for administering scopolamine transdermally |
| US4307717A (en) | 1977-11-07 | 1981-12-29 | Lectec Corporation | Sterile improved bandage containing a medicament |
| US4725439A (en) | 1984-06-29 | 1988-02-16 | Alza Corporation | Transdermal drug delivery device |
| IL80411A (en) | 1986-10-24 | 1991-08-16 | Raphael Mechoulam | Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them |
| IL115245A (en) | 1995-09-11 | 2002-12-01 | Yissum Res Dev Co | Tumor necrosis factor inhibiting pharmaceuticals |
| US6593456B1 (en) * | 1996-11-06 | 2003-07-15 | The Regents Of The University Of California | Tumor necrosis factor receptor releasing enzyme |
| EP1002535A1 (en) * | 1998-10-28 | 2000-05-24 | Hrissanthi Ikonomidou | New use of glutamate antagonists for the treatment of cancer |
| CA2411585A1 (en) | 2000-06-22 | 2001-12-27 | Pharmos Corporation | Novel non-psychotropic cannabinoids |
| EP1427404A4 (en) * | 2001-08-20 | 2005-10-26 | Maiken Nedergaard | TREATMENT OF GLIAL TUMORS WITH GLUTAMATE ANTAGONISTS |
| IL148736A0 (en) * | 2002-03-18 | 2002-09-12 | Pharmos Corp | Dexanabinol and dexanabinol analogs which regulate inflammation related genes |
| CN100459982C (zh) * | 2004-08-30 | 2009-02-11 | 鲁南制药集团股份有限公司 | 去氧氟尿苷的分散片剂型 |
| GB0713116D0 (en) * | 2007-07-06 | 2007-08-15 | Therapeutics Ltd E | Treatment of melanoma |
| GB0915877D0 (en) * | 2009-09-10 | 2009-10-14 | E Therapeutics Plc | Cancer cell apoptosis |
-
2009
- 2009-09-10 GB GBGB0915877.5A patent/GB0915877D0/en not_active Ceased
-
2010
- 2010-09-10 RU RU2012113875/15A patent/RU2592230C2/ru not_active IP Right Cessation
- 2010-09-10 NZ NZ598652A patent/NZ598652A/en not_active IP Right Cessation
- 2010-09-10 IN IN2412DEN2012 patent/IN2012DN02412A/en unknown
- 2010-09-10 CN CN2010800402207A patent/CN102573833A/zh active Pending
- 2010-09-10 US US13/390,832 patent/US20120190735A1/en not_active Abandoned
- 2010-09-10 AU AU2010294055A patent/AU2010294055B2/en not_active Ceased
- 2010-09-10 MX MX2012002992A patent/MX337433B/es active IP Right Grant
- 2010-09-10 CA CA2771099A patent/CA2771099A1/en not_active Abandoned
- 2010-09-10 BR BR112012005262A patent/BR112012005262A2/pt not_active IP Right Cessation
- 2010-09-10 JP JP2012528446A patent/JP5930204B2/ja not_active Expired - Fee Related
- 2010-09-10 MY MYPI2012000560A patent/MY161186A/en unknown
- 2010-09-10 KR KR1020127009159A patent/KR20120090060A/ko not_active Application Discontinuation
- 2010-09-10 CN CN201610095249.4A patent/CN105935357A/zh active Pending
- 2010-09-10 SG SG2012014528A patent/SG178604A1/en unknown
- 2010-09-10 WO PCT/GB2010/001710 patent/WO2011030106A1/en active Application Filing
- 2010-09-10 EP EP10765471A patent/EP2475364A1/en not_active Withdrawn
-
2012
- 2012-02-09 IL IL218008A patent/IL218008A/en not_active IP Right Cessation
- 2012-03-16 ZA ZA2012/01981A patent/ZA201201981B/en unknown
-
2015
- 2015-08-07 JP JP2015157063A patent/JP2015214579A/ja active Pending
-
2017
- 2017-10-03 US US15/723,450 patent/US20180042891A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013504550A (ja) | 2013-02-07 |
| BR112012005262A2 (pt) | 2016-03-15 |
| WO2011030106A1 (en) | 2011-03-17 |
| US20120190735A1 (en) | 2012-07-26 |
| JP2015214579A (ja) | 2015-12-03 |
| AU2010294055A1 (en) | 2012-04-05 |
| ZA201201981B (en) | 2013-05-29 |
| MX2012002992A (es) | 2012-07-17 |
| KR20120090060A (ko) | 2012-08-16 |
| MY161186A (en) | 2017-04-14 |
| GB0915877D0 (en) | 2009-10-14 |
| US20180042891A1 (en) | 2018-02-15 |
| EP2475364A1 (en) | 2012-07-18 |
| JP5930204B2 (ja) | 2016-06-08 |
| CN102573833A (zh) | 2012-07-11 |
| CA2771099A1 (en) | 2011-03-17 |
| NZ598652A (en) | 2014-05-30 |
| SG178604A1 (en) | 2012-04-27 |
| RU2592230C2 (ru) | 2016-07-20 |
| IL218008A0 (en) | 2012-04-30 |
| AU2010294055B2 (en) | 2014-10-02 |
| RU2012113875A (ru) | 2013-10-20 |
| IN2012DN02412A (es) | 2015-08-21 |
| IL218008A (en) | 2016-10-31 |
| CN105935357A (zh) | 2016-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG178604A1 (en) | Cancer cell apoptosis | |
| CA3035532C (en) | Psma-targeting compounds and uses thereof | |
| CL2010001018A1 (es) | Un cartucho transductor para ultrasonido conectado a un cuerpo para formar un cabezal para terapias. | |
| MX366503B (es) | Derivados de amatoxina. | |
| MY186824A (en) | Glucosylceramide synthase inhibitors | |
| EA201290901A1 (ru) | Фитоканнабиноиды для лечения злокачественной опухоли | |
| MX346379B (es) | Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (cdk4/6) y un inhibidor de mtor para tratar cancer. | |
| CL2008002319A1 (es) | Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. | |
| DOP2011000316A (es) | Anticuerpos anti-tnf-a y sus usos | |
| BR112012010614A8 (pt) | transdutor curvado de ultrassom focalizado de alta intensidade (hifu) | |
| ES2422739T3 (es) | Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB | |
| CO6640205A2 (es) | Microorganismos y metodos para la biosintesis de p-toluato y tereftalato | |
| CR20120035A (es) | Terapia combinatoria de un anticuerpo anti-cd20 afucosilado con fludarabina y/o mitoxantrona | |
| EP2329044A4 (en) | PRMT1 FOR TARGET GENES FOR THE TREATMENT AND DIAGNOSIS OF CANCER | |
| CL2009001643S1 (es) | Unidad aritmetica y de control para videojuego o similar, de cuerpo paralelepipedico rectangular de sector frontal mas arriba que el sector posterior; el sector posterior inferior tiene en su cara frontal cuatro ranuras circulares, las centrales de menor dimension. | |
| EP3693022A3 (en) | Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers | |
| CY1121859T1 (el) | Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης | |
| MX2009008247A (es) | Biomarcadores de respuesta a la radiacion ionizante. | |
| WO2015010782A8 (en) | Cancer therapy with a parvovirus combined with a bcl-2 inhibitor | |
| CO6382138A2 (es) | N-cadherina: blanco para diagnosis y terapia de cáncer | |
| EP2398901A4 (en) | JARID1B AS A TARGET GENE FOR ANTICANCER TREATMENT AND DIAGNOSIS OF CANCER | |
| IL197335A (en) | Sensitization of cancer cells to treatment @ radioactive @ B @ Y @ agonists @ of endothelin | |
| BRPI0815757A2 (pt) | Os genes pkib e naalad2 como alvos do tratamento e do diagnóstico do câncer de próstata | |
| EP4270007A3 (en) | Use of dna-transcription factor complexes for cancer detection | |
| EP2996677A4 (en) | Photosensitizer particles for medical imaging and/or photodynamic therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |